News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Revolutions Medical Corporation to Sell the RevVac™ Auto-Retractable Vacuum Safety Syringe in Brazil Through New Distributor Agntech


11/27/2012 10:37:06 AM

CHARLESTON, SC--(Marketwire - November 27, 2012) - Revolutions Medical Corporation ("Revolutions Medical" or the "Company") (OTCQB: RMCP) has received The Brazilian Health Surveillance Agency (Anvisa) certification to sell the RevVac™ safety syringe through its newly signed distributor Agntech.

Agntech is a company that has been operating in the Brazilian market for over 12 years with a corporate focus on the representation of commercial pharmaceutical products, medicines, hospital supplies, and a host of other machinery, equipment, and business services primarily for government and security forces (Army, Navy, Air Force, Federal highway police, Federal police, Military policemen, Civil and Municipal Guard).

Agntech has conducted numerous demonstrations of the RevVac™ safety syringe in different states, cities and municipalities over the past month and found a good acceptance of the auto-retractable vacuum safety syringe technology in the market. The country of Brazil has passed new health care safety regulations over the past few years and the RevVac™ safety syringe could be a perfect solution.

Carlos Carvalho, President of Agntech, stated, "Our Company works strictly within the laws of the federal, state and local governments with total transparency. We recently gained the approval by the regulatory body to participate in several public biddings for the sale of RevVac™ and we are confident that both Revolutions Medical and Agntech can achieve success in Brazil because of the positive feedback obtained through our marketing efforts."

Ron Wheet, Chief Executive Officer and Chairman, stated, "The opening of the Brazilian market for our RevVac™ safety syringe is a key milestone for our Company. Brazil is one of the leading countries in health care safety with government legislation driving the safety syringe market. The Company is planning another visit to the Yeso-med manufacturing facility in China in December to discuss increasing production capabilities of the 3ml and to put together the timeline for the roll out of the 1ml, including the tuberculin and insulin RevVac™ safety syringes, as well as the 5ml and 10ml."

About Revolutions Medical Corporation
Revolutions Medical is a safety medical device and software application company. Its proprietary technologies and products include: the RevVac™ safety syringe, safety blood drawing device, the RevColor™, RevDisplay™, and Rev3D™ software tools that are compatible with standard MRIs and standard Picture Archiving Computer Systems (PACS) and prefilled auto-retraction vacuum safety syringes.

For additional information, please visit Revolutions Medical corporate website:
http://www.revolutionsmedical.com/

To be added to the Revolutions Medical investor email list, please email:
investment@revolutionsmedical.com with RMCP in the subject line.

FORWARD-LOOKING STATEMENTS

The information contained herein includes forward-looking statements. These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.


CONTACT:

Revolutions Medical Corporation
Investor Relations
Tel.: (843) 606-9461


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES